Abstract:Adoptive T-cell transfer (ACT) therapies, including of tumor infiltrating lymphocytes (TILs) and T cells gene-modified to express either a T cell receptor (TCR) or a chimeric antigen receptor (CAR), have demonstrated clinical efficacy for a proportion of patients and cancer-types. The field of ACT has been driven forward by the clinical success of CD19-CAR therapy against various advanced B-cell malignancies, including curative responses for some leukemia patients. However, relapse remains problematic, in particular for lymphoma. Moreover, for a variety of reasons, relative limited efficacy has been demonstrated for ACT of non-hematological solid tumors. Indeed, in addition to pre-infusion challenges including lymphocyte collection and manufacturing, ACT failure can be attributed to several biological processes post-transfer including, (i) inefficient tumor trafficking, infiltration, expansion and retention, (ii) chronic antigen exposure coupled with insufficient costimulation resulting in T-cell exhaustion, (iii) a range of barriers in the tumor microenvironment (TME) mediated by both tumor cells and suppressive immune infiltrate, (iv) tumor antigen heterogeneity and loss, or down-regulation of antigen presentation machinery, (v) gain of tumor intrinsic mechanisms of resistance such as to apoptosis, and (vi) various forms of toxicity and other adverse events in patients. Affinity-optimized TCRs can improve T-cell function and innovative CAR designs as well as gene-modification strategies can be used to coengineer specificity, safety, and function into T cells. Coengineering strategies can be designed not only to directly support the transferred T cells, but also to block suppressive barriers in the TME and harness endogenous innate and adaptive immunity. Here, we review a selection of the remarkable T-cell coengineering strategies, including of tools, receptors, and gene-cargo, that have been developed in recent years to augment tumor control by ACT, more and more of which are advancing to the clinic.

Adoptive Cellular Therapy (ACT) for Cancer Treatment

Adoptive Cell Therapy of Gastric Cancer

Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities

Adoptive cell transfer as personalized immunotherapy for human cancer

Safety and Tolerability of Adoptive Cell Therapy in Cancer

Adoptive cell therapy of cancer-An old story with a new twist

ADOPTIVE CELL THERAPY: CURRENT ADVANCES

Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma

Enhanced cellular therapy: revolutionizing adoptive cellular therapy

Adoptive cellular therapy after hematopoietic stem cell transplantation

Adoptive immunotherapy for cancer: harnessing the T cell response

Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours

Adoptive Immunotherapy beyond CAR T-Cells

TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals

Coengineering specificity, safety, and function into T cells for cancer immunotherapy

Challenges and new technologies in adoptive cell therapy

Delivery Systems Developed for Treatment Combinations to Improve Adoptive Cell Therapy

Cell delivery devices for cancer immunotherapy

The potential and promise for clinical application of adoptive T cell therapy in cancer

Enhancing Adoptive Cell Therapy of Cancer Through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors

Optimizing Adoptive Cell Therapy for Solid Tumors via Epigenetic Regulation of T‐cell Destiny